semaglutide fda shortage Declares of Novo Nordisk's Wegovy, Ozempic Over US judge upholds FDA's removal

Initially, these medications were developed for the treatment of type 2 diabetes mellitus, but GLP-1 RA drugs have demonstrated remarkable outcomes in clinical settings

G.Molina-CastroG

Semaglutide therapy has become a cornerstone of modern weight loss treatment, with studies showing sustained body weight reduction of 10-22% over 68 weeks in clinical trials

NICE and British Society for Haematology guidelines recommend: Initial treatment with hydroxocobalamin (the preferred form in the UK) via intramuscular injection For patients without neurological involvement: 1 mg IM three times a week for 2 weeks For patients with neurological involvement: 1 mg IM on alternate days until no further improvement Maintenance: 1 mg every 3 months for patients without neurological involvement